Search form About Us Our Products Cumberland Emerging Technologies Investor Relations News Blog Contact Us Improving Care Cumberland Pharmaceuticals is on a mission to improve patient care through the delivery of high-quality pharmaceutical products. Learn More About Our Products Quality Products Vibativ is an FDA-approved treatment for certain serious bacterial infections with proven efficacy against difficult-to-treat Gram-positive infections. Learn More About Our Products Providing Solutions Caldolor is the first injectable approved in the U.S. to manage pain in adults and pediatric patients and has been shown to help reduce the need for opioids. Learn More About Our Products Supporting Patients Kristalose is the only prescription laxative product available in a powder formulation. Learn More About Our Products Expanding Our Pipeline With the addition of our Phase II candidate for patients with Duchenne muscular dystrophy, we are developing new medicines for the future. Learn More About Our Products Corporate Sustainability We support our mission through community involvement, ethical marketing, drug safety policies and more. View Sustainability Report 1 2 3 4 5 6 Learn more about recent company developments from Cumberland Pharmaceuticals’ Founder and Chief Executive Officer A.J. Kazimi. Read Message Recent News November 16, 2021 Cumberland Pharmaceuticals Moving Corporate Headquarters to Broadwest November 9, 2021 Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update View All CPIX (Common Stock) Exchange: NASDAQ Open: 2.24 Price: 2.23 Change: -0.05 (2.2%) Volume: 21,840 Data as of Friday 11/26/2021 12:59 PM E.T. Minimum 20 minute delay ©Cumberland Pharmaceuticals Inc. 2525 West End Avenue, Suite 950, Nashville, Tennessee 37203 ... ESG ReportSite MapPrivacy PolicyTerms & Conditions

Skip to main navigation Search form About Us Our Products Cumberland Emerging Technologies Investor Relations News Blog Contact Us Corporate Update Corporate Governance Stock Information Financial Information Events & Presentations Investor FAQs News Releases Contact IR Investor Relations 3 Mo. 6 Mo. 1 Yr. Shareholder Tools Search Investor Relations Contact Us Questions for the Investor Relations Department can be submitted through the form below. * Required fields Name Email Subject Comments Cumberland Pharmaceuticals Inc. 2525 West End Avenue, Suite 950, Nashville, Tennessee 37203 Site MapPrivacy PolicyTerms & Conditions